1. New Tools for the Urologist in the Management of Patients with Bone Metastases 
Bob Djavan 
European Urology Supplements 
Volume 6, Issue 11, Pages (June 2007)
DOI: /j.eursup
Copyright © 2007 European Association of Urology Terms and Conditions

2. Fig. 1
Patients with prostate cancer (PC) undergoing androgen-deprivation therapy (ADT) with a gonadotropin-releasing hormone (GnRH) agonist have an increased risk of bone fractures. Data from Smith MR et al [6].
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © 2007 European Association of Urology Terms and Conditions

3. Fig. 2
Guidance from an expert panel for bone health monitoring and treatment during androgen-deprivation therapy. *Rule out pathologic fracture from bone metastases. ADT: androgen-deprivation therapy; BMD: bone mineral density; DEXA: dual-energy X-ray absorptiometry; CT: computed tomography. Adapted with permission from Diamond TH et al [7].
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © 2007 European Association of Urology Terms and Conditions

4. Fig. 3
Zoledronic acid prolonged bone metastasis-free survival (BMFS) in a pilot study in patients with high-risk solid tumors. Adapted with permission from Mystakidou K et al [13].
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © 2007 European Association of Urology Terms and Conditions

5. Fig. 4
Percentage of the skeleton affected by bone disease (<4.6% or >4.6%) inversely correlates with survival in patients with prostate cancer. Adapted with permission from Macmillan Publishers Ltd: Noguchi M et al. Br J Cancer 2003;88:195–201, copyright 2003 [38].
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © 2007 European Association of Urology Terms and Conditions